TY - JOUR
T1 - Capnography-assisted learned, monitored (CALM) breathing therapy for dysfunctional breathing in COPD
T2 - A bridge to pulmonary rehabilitation
AU - Norweg, Anna
AU - Hofferber, Brittany
AU - Oh, Cheongeun
AU - Spinner, Michael
AU - Stavrolakes, Kimberly
AU - Pavol, Marykay
AU - DiMango, Angela
AU - Raveis, Victoria H.
AU - Murphy, Charles G.
AU - Allegrante, John P.
AU - Buchholz, David
AU - Zarate, Alejandro
AU - Simon, Naomi
N1 - Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/11
Y1 - 2023/11
N2 - Background: Although dyspnea is a primary symptom of chronic obstructive pulmonary disease (COPD), its treatment is suboptimal. In both COPD and acute anxiety, breathing patterns become dysregulated, contributing to abnormal CO2, dyspnea, and inefficient recovery from breathing challenges. While pulmonary rehabilitation (PR) improves dyspnea, only 1–2% of patients access it. Individuals with anxiety who use PR have worse outcomes. Methods: We present the protocol of a randomized controlled trial designed to determine the feasibility and acceptability of a new, four-week mind-body intervention that we developed, called “Capnography-Assisted Learned, Monitored (CALM) Breathing,” as an adjunct to PR. Eligible participants are randomized in a 1:1 ratio to either CALM Breathing program or Usual Care. CALM Breathing consists of 10 core, slow breathing exercises combined with real time biofeedback (of end-tidal CO2, respiratory rate, and airflow) and motivational interviewing. CALM Breathing promotes self-regulated breathing, linking CO2 changes to dyspnea and anxiety symptoms and targeting breathing efficiency and self-efficacy in COPD. Participants are randomized to CALM Breathing or a Usual Care control group. Results: Primary outcomes include feasibility and acceptability metrics of recruitment efficiency, participant retention, intervention adherence and fidelity, PR facilitation, patient satisfaction, and favorable themes from interviews. Secondary outcomes include breathing biomarkers, symptoms, health-related quality of life, six-minute walk distance, lung function, mood, physical activity, and PR utilization and engagement. Conclusion: By disrupting the cycle of dyspnea and anxiety, and providing a needed bridge to PR, CALM Breathing may address a substantive gap in healthcare and optimize treatment for patients with COPD.
AB - Background: Although dyspnea is a primary symptom of chronic obstructive pulmonary disease (COPD), its treatment is suboptimal. In both COPD and acute anxiety, breathing patterns become dysregulated, contributing to abnormal CO2, dyspnea, and inefficient recovery from breathing challenges. While pulmonary rehabilitation (PR) improves dyspnea, only 1–2% of patients access it. Individuals with anxiety who use PR have worse outcomes. Methods: We present the protocol of a randomized controlled trial designed to determine the feasibility and acceptability of a new, four-week mind-body intervention that we developed, called “Capnography-Assisted Learned, Monitored (CALM) Breathing,” as an adjunct to PR. Eligible participants are randomized in a 1:1 ratio to either CALM Breathing program or Usual Care. CALM Breathing consists of 10 core, slow breathing exercises combined with real time biofeedback (of end-tidal CO2, respiratory rate, and airflow) and motivational interviewing. CALM Breathing promotes self-regulated breathing, linking CO2 changes to dyspnea and anxiety symptoms and targeting breathing efficiency and self-efficacy in COPD. Participants are randomized to CALM Breathing or a Usual Care control group. Results: Primary outcomes include feasibility and acceptability metrics of recruitment efficiency, participant retention, intervention adherence and fidelity, PR facilitation, patient satisfaction, and favorable themes from interviews. Secondary outcomes include breathing biomarkers, symptoms, health-related quality of life, six-minute walk distance, lung function, mood, physical activity, and PR utilization and engagement. Conclusion: By disrupting the cycle of dyspnea and anxiety, and providing a needed bridge to PR, CALM Breathing may address a substantive gap in healthcare and optimize treatment for patients with COPD.
KW - Biofeedback
KW - COPD
KW - Dysfunctional breathing
KW - Dyspnea
KW - Mind body
UR - http://www.scopus.com/inward/record.url?scp=85172226572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172226572&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2023.107340
DO - 10.1016/j.cct.2023.107340
M3 - Article
C2 - 37730198
AN - SCOPUS:85172226572
SN - 1551-7144
VL - 134
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
M1 - 107340
ER -